Share on StockTwits

Maximus (NYSE:MMS) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday, reports. They currently have a $53.80 target price on the stock. Zacks‘ price target would indicate a potential upside of 23.06% from the company’s current price.

Maximus (NYSE:MMS) traded down 1.11% during mid-day trading on Monday, hitting $43.72. The stock had a trading volume of 381,056 shares. Maximus has a 52 week low of $33.30 and a 52 week high of $50.55. The stock’s 50-day moving average is $43.80 and its 200-day moving average is $42.49. The company has a market cap of $2.996 billion and a P/E ratio of 26.41.

Maximus (NYSE:MMS) last issued its quarterly earnings data on Friday, November 15th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.01. The company had revenue of $384.30 million for the quarter, compared to the consensus estimate of $359.35 million. During the same quarter in the previous year, the company posted $0.37 earnings per share. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. Analysts expect that Maximus will post $1.86 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, February 28th. Stockholders of record on Friday, February 14th will be given a dividend of 0.045 per share. This represents a $0.18 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date of this dividend is Wednesday, February 12th.

Separately, analysts at Jefferies Group raised their price target on shares of Maximus from $47.00 to $53.00 in a research note to investors on Monday, November 18th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $61.20.

MAXIMUS, Inc is a provider of business process services (NYSE:MMS) to government health and human services agencies under its mission of Helping Government Serve the People.

To view Zacks’ full report, visit

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.